KR940701256A - 판토프라졸 함유 약제의 경구 투여 형태 - Google Patents

판토프라졸 함유 약제의 경구 투여 형태

Info

Publication number
KR940701256A
KR940701256A KR1019930703898A KR930703898A KR940701256A KR 940701256 A KR940701256 A KR 940701256A KR 1019930703898 A KR1019930703898 A KR 1019930703898A KR 930703898 A KR930703898 A KR 930703898A KR 940701256 A KR940701256 A KR 940701256A
Authority
KR
South Korea
Prior art keywords
resistant
drug
physiologically
hydroxypropylmethylcellulose
polyvinylpyrrolidone
Prior art date
Application number
KR1019930703898A
Other languages
English (en)
Other versions
KR100254021B1 (ko
Inventor
랑고 디트리히
하르트무트 네이
Original Assignee
허버트 서키, 울리히 울프
빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4218617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR940701256(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 허버트 서키, 울리히 울프, 빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하 filed Critical 허버트 서키, 울리히 울프
Publication of KR940701256A publication Critical patent/KR940701256A/ko
Application granted granted Critical
Publication of KR100254021B1 publication Critical patent/KR100254021B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

본 발명은 코어, 중간물질 층 및 위액에 내성을 갖는 최외층으로 구성된 판토프라졸용 경구 투여 형태에 관한 것이다.

Description

판토프라졸 함유 약제의 경구 투여 형태
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. -활성 화합물 또는 이의 생리학적으로 내성을 갖는 염이 하나이상의 결합제, 충전제, 필요할 경우 다른 정제 보조제, 및 필요할 경우, 하나이상의 생리학적으로 내성을 갖는 염기성 무기 화합물과의 혼합물로서 존재하는 코어; -상기 코어를 둘러싸고 있는 하나이상의 불활성, 수용성 중간물질 층, 및 -위액에 내성을 갖는 최외층으로 구성되고, 위액에 내성이 있으며, 경구 투여되는 펠릿 또는 정제 형태의 약물에 있어서, 상기 코어내에 판토프라졸이 활성 화합물로서 사용되고, 폴리비닐피롤리돈 및/또는 히드록시프로필메틸셀룰로서가 결합제로서 사용되고, 필요할 경우, 만니톨이 충전제로서 사용되는 것을 특징으로 하는 약물.
  2. 제1항에 있어서, 폴리비닐피롤린돈 및/또는 히드록시프로필메틸셀룰로스가 결합제로서 사용되고, 만니톨이 충전제로서 사용되는 것을 특징으로 하는 정제 형태의 약물.
  3. 제1항에 있어서, 폴리비닐피롤리돈 및/또는 히드록시프로필메틸셀룰로스가 결합제로서 사용되는 것을 특징으로 하는 펠릿 형태의 약물.
  4. 제1항 내지 제3항중 어느 한 항에 있어서, 판토프라졸-나트륨이 생리학적으로 내성이 있는 활성 화합물 염으로서 사용되는 것을 특징으로 하는 약물.
  5. 제1항 내지 제3항 중 어느 한 항에 있어서, 약산의 약물학적으로 내성을 갖는 알칼리 금속염, 알칼리 토금속염 또는 토류 금속염 또는 알칼리 토금속 또는 토류 금속의 약물학적으로 내성을 갖는 수산화물 또는 산화물을 생리학적으로 내성을 갖는 염기성 무기 화합물로 사용하는 것을 특징으로 하는 약제.
  6. 제1항 내지 제3항중 어느 한 항에 있어서, 탄산나트륨을 생리학적으로 내성을 갖는 염기성 무기 화합물로 사용하는 것을 특징으로 하는 약물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930703898A 1991-06-17 1992-06-13 판토프라졸 함유 약제의 경구 투여 형태 KR100254021B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH1788/91-0 1991-06-17
CH178891 1991-06-17
PCT/EP1992/001341 WO1992022284A1 (de) 1991-06-17 1992-06-13 Pantoprazol enthaltende orale darreichungsformen

Publications (2)

Publication Number Publication Date
KR940701256A true KR940701256A (ko) 1994-05-28
KR100254021B1 KR100254021B1 (ko) 2000-05-01

Family

ID=4218617

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930703898A KR100254021B1 (ko) 1991-06-17 1992-06-13 판토프라졸 함유 약제의 경구 투여 형태

Country Status (34)

Country Link
US (1) US5997903A (ko)
EP (2) EP0589981B1 (ko)
JP (1) JP3338052B2 (ko)
KR (1) KR100254021B1 (ko)
CN (1) CN1037932C (ko)
AT (1) ATE144416T1 (ko)
AU (1) AU683411B2 (ko)
BG (1) BG61796B1 (ko)
CA (2) CA2524168A1 (ko)
CZ (1) CZ281697B6 (ko)
DE (2) DE4219390A1 (ko)
DK (1) DK0589981T3 (ko)
ES (1) ES2096080T3 (ko)
FI (1) FI101598B (ko)
GR (1) GR3022154T3 (ko)
HK (1) HK1005851A1 (ko)
HR (1) HRP920162B1 (ko)
IE (1) IE77640B1 (ko)
IL (1) IL102096A (ko)
LV (1) LV11982B (ko)
MX (1) MX9202961A (ko)
NO (1) NO303714B1 (ko)
NZ (1) NZ243147A (ko)
PL (1) PL169951B1 (ko)
RO (1) RO117502B1 (ko)
RU (1) RU2089180C1 (ko)
SI (1) SI9200111A (ko)
SK (1) SK278566B6 (ko)
TW (1) TW224429B (ko)
UA (1) UA32525C2 (ko)
WO (1) WO1992022284A1 (ko)
YU (1) YU48263B (ko)
ZA (1) ZA924386B (ko)
ZW (1) ZW9392A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100657835B1 (ko) * 1998-08-18 2006-12-15 알타나 파마 아게 판토프라졸의 신규한 염 형태

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4504000A (en) * 1993-04-27 2000-09-07 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
DE4324014C2 (de) * 1993-07-17 1995-06-08 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung einer in Wasser rekonstituierbaren Zubereitung
TW280770B (ko) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
UA41946C2 (uk) * 1994-07-08 2001-10-15 Астра Актієболаг Оральна фармацевтична складова одинична дозована форма у вигляді таблетки, спосіб її одержання, упаковка у вигляді блістера та спосіб інгібування секреції шлункової кислоти і/або лікування шлунково-кишкових запальних захворювань
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
PL186605B1 (pl) * 1995-09-21 2004-01-30 Pharma Pass Llc Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
ATE500815T1 (de) * 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
US20020039597A1 (en) * 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
ES2559766T3 (es) 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
SI1105105T1 (sl) 1998-08-12 2006-08-31 Altana Pharma Ag Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole
ATE300285T1 (de) 1999-06-07 2005-08-15 Altana Pharma Ag Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
KR20020038759A (ko) 1999-10-20 2002-05-23 다니구치 미즈오 벤즈이미다졸계 화합물 안정화 방법
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
DK1108425T3 (da) * 1999-12-16 2005-09-26 Medinfar Produtos Farmaceutico Nye, stabile flerenhedspræparater, der indeholder substituerede benzimidazoler
SK287105B6 (sk) * 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
AU2277101A (en) * 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002045692A1 (en) * 2000-12-07 2002-06-13 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
BR0212950A (pt) 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas tendo uma porção inserida
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8449911B2 (en) * 2003-03-12 2013-05-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
WO2004098573A1 (en) * 2003-05-08 2004-11-18 Natco Pharma Limited An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US20050147663A1 (en) * 2003-07-17 2005-07-07 Mohan Mailatur S. Method of treatment for improved bioavailability
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
KR20060065632A (ko) * 2003-07-17 2006-06-14 닥터 레디스 래보러토리즈, 인코포레이티드 팽창성 코팅을 갖는 약제학적 조성물
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1670469A1 (en) * 2003-09-18 2006-06-21 ALTANA Pharma AG Use of known active ingredients as radical scavengers
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
CA2543172A1 (en) * 2003-10-31 2005-05-19 Dexcel Ltd. Stable lansoprazole formulation
WO2005046634A2 (de) * 2003-11-14 2005-05-26 Siegfried Generics International Ag Magensaftresistente verabreichungsform
HU227317B1 (en) * 2003-11-25 2011-03-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Enteric coated tablet containing pantoprazole
EP1694300A4 (en) * 2003-12-09 2009-04-29 Pharmasset Inc DOSAGE PROCESS FOR BETA-D-2 ', 3'-DIDEOXY-2', 3'-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
KR20070010132A (ko) * 2004-03-25 2007-01-22 아스텔라스세이야쿠 가부시키가이샤 솔리페나신 또는 그의 염의 고형 제제용 조성물
EP1728512A1 (en) * 2004-03-26 2006-12-06 Eisai R&D Management Co., Ltd. Controlled-leaching preparation and process for producing the same
CA2565083C (en) 2004-05-07 2014-07-08 Altana Pharma Ag Novel pharmaceutical dosage form and manufacturing process
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
EP1830822A1 (en) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
CA2591761A1 (en) * 2004-12-27 2006-07-06 Astellas Pharma Inc. Stable particulate pharmaceutical composition of solifenacin or salt thereof
WO2006085335A2 (en) * 2005-01-03 2006-08-17 Lupin Limited Pharmaceutical composition of acid labile substances
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
EP1895990A2 (en) * 2005-05-13 2008-03-12 Combino Pharm, S.L. Formulations containing pantoprazole free acid and its salts
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
CA2634232C (en) 2005-12-28 2013-08-20 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
US8865212B2 (en) 2006-01-16 2014-10-21 Jubilant Generics Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
SI2124884T1 (sl) 2006-12-22 2019-09-30 Ironwood Pharmaceuticals, Inc. Pripravki, ki obsegajo sekvestrante žolčnih kislin, za zdravljenje motenj požiralnika
WO2009034558A2 (en) 2007-09-14 2009-03-19 Wockhardt Research Centre Rhein or diacerein compositions
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
DE102010052847A1 (de) * 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
WO2014113377A1 (en) 2013-01-15 2014-07-24 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108065443B (zh) * 2017-12-30 2020-02-28 厦门金达威维生素有限公司 斥水型双包被微胶囊及其制备方法
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100657835B1 (ko) * 1998-08-18 2006-12-15 알타나 파마 아게 판토프라졸의 신규한 염 형태

Also Published As

Publication number Publication date
FI935677A0 (fi) 1993-12-16
LV11982B (lv) 1998-09-20
ZA924386B (en) 1993-02-24
US5997903A (en) 1999-12-07
KR100254021B1 (ko) 2000-05-01
ZW9392A1 (en) 1993-02-17
IL102096A0 (en) 1993-01-14
FI101598B1 (fi) 1998-07-31
CN1037932C (zh) 1998-04-08
UA32525C2 (uk) 2001-02-15
RO117502B1 (ro) 2002-04-30
CA2524168A1 (en) 1992-12-23
FI935677A (fi) 1993-12-16
SK128793A3 (en) 1994-06-08
BG98286A (bg) 1994-08-30
CA2109697A1 (en) 1992-12-23
HRP920162A2 (en) 1996-08-31
EP0589981A1 (de) 1994-04-06
AU683411B2 (en) 1997-11-13
EP0589981B1 (de) 1996-10-23
BG61796B1 (bg) 1998-06-30
IL102096A (en) 1996-06-18
ATE144416T1 (de) 1996-11-15
NO934648D0 (no) 1993-12-16
YU48263B (sh) 1997-09-30
CA2109697C (en) 2005-11-22
PL169951B1 (pl) 1996-09-30
NO303714B1 (no) 1998-08-24
HK1005851A1 (en) 1999-01-29
HRP920162B1 (en) 1998-08-31
AU1974692A (en) 1993-01-12
ES2096080T3 (es) 1997-03-01
IE77640B1 (en) 1997-12-31
CZ281697B6 (cs) 1996-12-11
DK0589981T3 (da) 1997-03-17
IE921733A1 (en) 1992-11-18
CN1067809A (zh) 1993-01-13
JPH06508118A (ja) 1994-09-14
MX9202961A (es) 1993-02-01
FI101598B (fi) 1998-07-31
DE59207438D1 (de) 1996-11-28
NO934648L (no) 1993-12-16
SI9200111A (en) 1992-12-31
NZ243147A (en) 1995-12-21
CZ276493A3 (en) 1994-07-13
JP3338052B2 (ja) 2002-10-28
WO1992022284A1 (de) 1992-12-23
SK278566B6 (en) 1997-10-08
YU57692A (sh) 1995-03-27
EP0519365A1 (de) 1992-12-23
LV11982A (lv) 1998-03-20
DE4219390A1 (de) 1992-12-24
RU2089180C1 (ru) 1997-09-10
GR3022154T3 (en) 1997-03-31
TW224429B (ko) 1994-06-01

Similar Documents

Publication Publication Date Title
KR940701256A (ko) 판토프라졸 함유 약제의 경구 투여 형태
AU719170B2 (en) Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
AU781718B2 (en) Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
AU774723B2 (en) Pharmaceutical composition with gastric residence and controlled release
EP1411900B2 (en) PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
HRP20121005T1 (hr) Dozirani oblik koji sadrži pantoprazol kao aktivni sastojak
DE60123384D1 (de) Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
CO4940409A1 (es) Tableta cubierta con pelicula para seguridad mejorada del tracto gastrointestinal superior
IL150696A0 (en) Pharmaceutical compositions containing benzimidazole derivatives and processes for the manufacture thereof
HK1083452A1 (en) Pharmaceutical compositions
ES2162874T3 (es) Composicion farmaceutica para hacer llegar medicamentos hasta el colon.
KR850700212A (ko) 서방성 약제학적 캼셀제
JP2008533127A5 (ko)
GEP20063882B (en) Dosage regimen and pharmaceutical composition for emergency contraception
KR960000217A (ko) L- 카르니틴염과 이를 함유한 조성물
KR900015724A (ko) 메베버린 용량 형태
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
NL194907C (nl) Farmaceutische samenstellingen die furaanderivaten bevatten.
CA2524979A1 (en) Solid dosage form comprising (s)-pantoprazole magnesium salt
AU4127599A (en) Pharmaceutical tablets comprising an nsaid and a prostaglandin
NZ193239A (en) Anti-inflammatory compositions containing 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid and a 2-hydroxy-5-halophenylbenzoic acid derivative
Zargar et al. Rifampicin-induced upper gastrointestinal bleeding
US3155576A (en) Ulcer therapy composition and method of using same
JPS5865215A (ja) 医薬組成物
AU677108B2 (en) Ranitidine and calcium carbonate pharmaceutical combination product

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
J206 Request for trial to confirm the scope of a patent right
J301 Trial decision

Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20050824

Effective date: 20060330

FPAY Annual fee payment

Payment date: 20120109

Year of fee payment: 13

EXPY Expiration of term